Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review

被引：3

作者：

Hotta, Masaaki ^{[1
]}

Ito, Tomoki ^{[1
]}

Konishi, Akiko ^{[1
]}

Yoshimura, Hideaki ^{[1
]}

Nakanishi, Takahisa ^{[1
]}

Fujita, Shinya ^{[1
]}

Satake, Atsushi ^{[1
]}

Nomura, Shosaku ^{[1
]}

机构：

[1] Kansai Med Univ, Dept Internal Med 1, Hirakata, Osaka, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 03期

关键词：

multiple myeloma; central nerves system; pomalidmide; intrathecal chemotherapy; craniospinal radiation; LOW-DOSE DEXAMETHASONE; INTRATHECAL CHEMOTHERAPY; INVOLVEMENT; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE; THERAPY; PLASMACYTOMA; RADIOTHERAPY; DARATUMUMAB;

D O I：

10.2169/internalmedicine.5646-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe a 45-year-old woman who had MM (diagnosed with IgA-ic type) with CNS relapse early after undergoing autologous hematopoietic stem cell transplantation. Because no standard treatment for CNS lesions of MM has been established, we conducted a literature review on the cerebrospinal fluid (CSF) transferability of drugs for MM, since it was considered to be a useful tool for CNS involvement. Immunomodulatory-drugs including pomalidomide exhibit a good CSF transfer ability, and, therefore, may be beneficial against the CNS involvement of MM.

引用

页码：463 / 468

页数：6

共 34 条

[1] Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma [J].

Abdallah, Al-ola ;

Atrash, Shebli ;

Shahid, Zainab ;

Jameel, Muzaffar ;

Grazziutti, Monica ;

Apewokin, Senu ;

Kumar, Naveen S. ;

Restrepo, Alejandro ;

Waheed, Sarah ;

Van Rhee, Frits ;

Heuck, Christoph J. ;

Johann, Donald, Jr. ;

Barlogie, Bart ;

Usmani, Saad Z. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03) :211-214

[2] Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma [J].

Anwer, Saiyed ;

Collings, Freya ;

Trace, Kim ;

Sun, Yongkai ;

Sternberg, Alexander .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) :281-282

[3] Aggressive Central Nervous System Relapse after Autologous Stem Cell Transplant in Multiple Myeloma: Case Reports and Literature Review [J].

Bergantim, Rui ;

Bastos, Juliana ;

Soares, Maria Jose ;

Carvalho, Bruno ;

Soares, Pedro ;

Marques, Cristina ;

Costa, Jennifer ;

Guimaraes, Jose Eduardo ;

Trigo, Fernanda .

CASE REPORTS IN HEMATOLOGY, 2020, 2020

[4] Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions [J].

Chang, H ;

Sloan, S ;

Li, D ;

Stewart, AK .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :280-284

[5] Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents [J].

Chen, Christine I. ;

Masih-Khan, Esther ;

Jiang, Haiyan ;

Rabea, Ahmed ;

Cserti-Gazdewich, Christine ;

Jimenez-Zepeda, Victor H. ;

Chu, Chia-Min ;

Kukreti, Vishal ;

Trudel, Suzanne ;

Tiedemann, Rodger ;

Tsang, Richard ;

Reece, Donna E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (04) :483-488

[6] The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide [J].

Devoe, Craig E. ;

Li, Jian Yi ;

Demopoulos, Alexis M. .

JOURNAL OF NEURO-ONCOLOGY, 2014, 119 (01) :217-220

[7] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[8] Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab [J].

Elhassadi, Ezzat ;

Murphy, Maurice ;

Hacking, Dayle ;

Farrell, Michael .

CLINICAL CASE REPORTS, 2018, 6 (04) :723-728

[9] Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations [J].

Fassas, ABT ;

Muwalla, F ;

Berryman, T ;

Benramdane, R ;

Joseph, L ;

Anaissie, E ;

Sethi, R ;

Desikan, R ;

Siegel, D ;

Badros, A ;

Toor, A ;

Zangari, M ;

Morris, C ;

Angtuaco, E ;

Mathew, S ;

Wilson, C ;

Hough, A ;

Harik, S ;

Barlogie, B ;

Tricot, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :103-108

[10] Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients [J].

Gozzetti, Alessandro ;

Cerase, Alfonso ;

Lotti, Flavia ;

Rossi, Davide ;

Palumbo, Antonio ;

Petrucci, Maria Teresa ;

Patriarca, Francesca ;

Nozzoli, Chiara ;

Cavo, Michele ;

Offidani, Massimo ;

Floridia, Michele ;

Berretta, Salvatore ;

Vallone, Roberto ;

Musto, Pellegrino ;

Lauria, Francesco .

CANCER, 2012, 118 (06) :1574-1584

← 1 2 3 4 →